Treatment-related factors and highly active antiretroviral therapy adherence

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue SUPPL. 3, 2002, Pages

  Trotta, Maria Paola ^a   Ammassari, Adriana ^b   Melzi, Sara ^c   Zaccarelli, Mauro ^a   Ladisa, Nicoletta ^d   Sighinolfi, Laura ^e   Mura, Maria Stella ^f   D'Arminio Monforte, Antonella ^c   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

Author keywords

Adherence; Antiretroviral therapy; Complexity; HAART; HIV AIDS; Side effects

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL TRIAL; CONFERENCE PAPER; DIETARY INTAKE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLNESS BEHAVIOR; LIFESTYLE; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SYMPTOM; TABLET FORMULATION;

EID: 0037114852     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200212153-00008     Document Type: Conference Paper

References (21)

1. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-77.
2. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-9.
3. Gifford AL, Bormann JE, Shivley MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-95.
4. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instrument. AIDS Care 2000;12:255-66.
5. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr 1998;18:117-25.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-reported and electronic monitoring. Clin Infect Dis 2001;33:1417-23.
8. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr 2001;28:124-31.
9. Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161: 1962-8.
10. Altice FL, Mostashari F, Friedland GH. Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28:47-58.
11. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2001;26:82-92.
12. Singh N, Berman SM, Swindells S, et al. Adherence to human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-30.
13. Antinori A, Trotta MP, Cozzi Lepri A, et al. Adherence to antiretroviral therapy: Comparative analysis of protease inhibitors-based and non-nucleoside reverse transcriptase inhibitors-based regimens [abstract WePeB5852]. Presented at the XIV International AIDS Conference, Barcelona, July 7-12, 2002.
14. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.
15. Fumaz C, Tuldrà A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002;29:244-53.
16. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
17. Grimes RM, Lal L, Lewis ST. Frequency and medical history items, drug interactions, and lifestyle characteristics that may interfere with antiretroviral medications. HIV Clin Trials 2002;3: 161-7.
18. Gallant JE, Block DS. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. J Int Assoc Phys AIDS Care 1998;4:32-5.
19. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45.
20. Eron JJ, Yetzer ES, Ruane PJ, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 2000; 14:671-81.
21. Katlama C, Clumeck N, Fenske S, et al. Use of trizivir to simplify therapy in HAART-experienced patients with long-term suppression of HIV-RNA: TRIZIAL Study (AZL30002). 24-Week results [abstract 316]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001.